http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-094562-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_ef2e9f5ce8630d9b282043b8d060caff http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0bb6db818f0c67efdde3038c80baaacf |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4725 |
| filingDate | 2014-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_182b192cceeff8550f341b41aff207e4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_143644b3d6d64844f3e0c3dc9086b7eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_68493a9013b88f90cfac656c3539d0d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcf0b83aede48b07410f235597ba348f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e2adaa2a467c2e34fe2b430c5cb3b9e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7178196594588793804766e949327986 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_148c383738fdf24d213151812795f0d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_025bd030677eeba905ab8f95db03dd58 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ba303280a3c096c220dd6d307f0b3303 |
| publicationDate | 2015-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-094562-A1 |
| titleOfInvention | ISOQUINOLINE COMPOSITE REPLACED AND PHARMACEUTICAL COMPOSITION THAT INCLUDES IT |
| abstract | A substituted isoquinoline compound which is of the formula (1) or a pharmaceutically acceptable salt thereof, wherein: R¹ is selected from the group of H, optionally substituted C₁₋₆ alkyl, optionally substituted C₃₋₆ cycloalkyl and optionally substituted aryl; R² is H; R³ and R⁴ independently represent a C₁₋₃ alkyl group; R⁵ is H; R⁶ and R⁷, are independently H; R is H or C₁₋₆ alkyl; Ar is selected from the group consisting of: an optionally substituted nine to ten membered heteroaryl fused, an optionally substituted benzo fused aryl, optionally substituted benzo fused heteroaryl, optionally substituted benzo fused heterocyclyl, and optionally substituted benzo fused cycloalkyl, wherein two optional substituents at the adjacent positions of each of said optionally substituted nine to ten membered heteroaryl, optionally substituted benzo aryl, optionally substituted benzo heteroaryl, optionally substituted benzo heterocyclyl, and benzo fused cycloalkyl Optionally substituted can be taken together with atoms that are attached to form an aryl. Pharmaceutical composition comprising at least one compound as described, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier. These compounds are useful as phosphodiesterase 10 (PDE10A) inhibitors, applicable in the treatment of diseases of the central nervous system such as psychosis, as well as in the treatment, for example, of obesity, diabetes mellitus type II, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases. |
| priorityDate | 2014-01-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8405 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID407559142 |
Total number of triples: 22.